Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells.

Because of the heterogeneous nature of prostate cancer, identifying the molecular mechanisms involved during the transition from an androgen-sensitive to an androgen-independent phenotype is very complex. An LNCaP cell model that recapitulates prostate cancer progression, comprising early passage androgen-sensitive (LNCaP-C33) and late passage androgen-independent (LNCaP-C81) phenotypes, would help to provide a better understanding of such molecular events. In this study, we examined the genes expressed by LNCaP-C33 and LNCaP-C81 cells using cDNA microarrays containing 1176 known genes. This analysis demonstrated that 34 genes are up-regulated and eight genes are down-regulated in androgen-independent cells. Northern blot analysis confirmed the differences identified by microarrays on several candidate genes, including c-MYC, c-MYC purine-binding transcription factor (PuF), macrophage migration inhibitory factor (MIF), macrophage inhibitory cytokine-1 (MIC-1), lactate dehydrogenase-A (LDH-A), guanine nucleotide-binding protein Gi, alpha-1 subunit (NBP), cyclin dependent kinase-2 (CDK-2), prostate-specific membrane antigen (PSM), cyclin H (CCNH), 60S ribosomal protein L10 (RPL10), 60S ribosomal protein L32 (RPL32), and 40S ribosomal protein S16 (RPS16). These differentially-regulated genes are correlated with progression of human prostate cancer and may be of therapeutic relevance as well as an aid in understanding the molecular genetic events involved in the development of this disease's hormone-refractory behavior.

[1]  S. Batra,et al.  Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell model , 2002, The Prostate.

[2]  B. Dave,et al.  Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Welsh,et al.  Molecular classification of human carcinomas by use of gene expression signatures. , 2001, Cancer research.

[4]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[5]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[6]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[7]  G. Muir,et al.  Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray , 2001, British Journal of Cancer.

[8]  T. Takagi,et al.  Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. , 2001, Cancer research.

[9]  David Handelsman,et al.  Identification of differentially expressed genes in organ‐confined prostate cancer by gene expression array , 2001, The Prostate.

[10]  W. D. Fairlie,et al.  The Propeptide of the Transforming Growth Factor-β Superfamily Member, Macrophage Inhibitory Cytokine-1 (MIC-1), Is a Multifunctional Domain That Can Facilitate Protein Folding and Secretion* , 2001, The Journal of Biological Chemistry.

[11]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Vikram,et al.  Cell lines from the same cervical carcinomabut with different radiosensitivities exhibit different cDNA microarray patterns of gene expression , 2001, Cytogenetic and Genome Research.

[13]  M. Cintorino,et al.  Macrophage migration inhibitory factor in prostatic adenocarcinoma: Correlation with tumor grading and combination endocrine treatment‐related changes , 2000, The Prostate.

[14]  D. Moras,et al.  Molecular Structure of Human TFIIH , 2000, Cell.

[15]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[16]  A. Rizzino,et al.  DNA microarray analyses of genes regulated during the differentiation of embryonic stem cells , 2000, Molecular reproduction and development.

[17]  S. Reed,et al.  Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. , 2000, Cancer research.

[18]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[19]  A. Vlahou,et al.  Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[21]  W. Yung,et al.  Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. , 1999, Cancer research.

[22]  F. Agou,et al.  Single Strand DNA Specificity Analysis of Human Nucleoside Diphosphate Kinase B* , 1999, The Journal of Biological Chemistry.

[23]  N. Goldstein,et al.  Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells , 1999, Oncogene.

[24]  M. Cintorino,et al.  Macrophage migration inhibitory factor in the human prostate: Identification and immunocytochemical localization , 1999, The Prostate.

[25]  Emmett V Schmidt,et al.  The role of c-myc in cellular growth control , 1999, Oncogene.

[26]  R. Weigel,et al.  GATA‐3 is expressed in association with estrogen receptor in breast cancer , 1999, International journal of cancer.

[27]  L. Hood,et al.  Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.

[28]  W. D. Fairlie,et al.  MIC‐1 is a novel TGF‐β superfamily cytokine associated with macrophage activation , 1999, Journal of leukocyte biology.

[29]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[30]  Wei Zhang,et al.  Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[32]  M. Böhm.  Catecholamine Refractoriness and their Mechanisms in Cardiocirculatory Shock and Chronic Heart Failure , 1998, The Thoracic and cardiovascular surgeon.

[33]  S. Jiang,et al.  Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. , 1998, The American journal of pathology.

[34]  D. Bostwick,et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.

[35]  S. Vukicevic,et al.  Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.

[36]  R. Young,et al.  Application of the differential hybridization of Atlas™ human expression arrays technique in the identification of differentially expressed genes in human glioblastoma multiforme tumor tissue , 1998, Journal of surgical oncology.

[37]  A. Schönthal,et al.  Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines* , 1998, The Journal of Biological Chemistry.

[38]  J. Bernhagen,et al.  Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features , 1998, Journal of Molecular Medicine.

[39]  X. Chen,et al.  p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner , 1997, Molecular and cellular biology.

[40]  R. Bucala,et al.  Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. , 1997, Molecular medicine today.

[41]  I. McKillop,et al.  Alterations in guanine nucleotide regulatory protein expression and activity in human hepatocellular carcinoma , 1997, Hepatology.

[42]  W. D. Fairlie,et al.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Nakayama,et al.  Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. , 1997, Cancer research.

[45]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[46]  K. Meyer-Siegler,et al.  Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. , 1996, Urology.

[47]  P. Kopp,et al.  Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. , 1996, The Journal of clinical endocrinology and metabolism.

[48]  K. Ryan,et al.  Myc oncogenes: the enigmatic family. , 1996, The Biochemical journal.

[49]  H. Miyajima,et al.  Characterization of the glycolysis in lactate dehydrogenase‐A deficiency , 1995, Muscle & nerve.

[50]  W. Fair,et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.

[51]  Y. Rochon,et al.  Western blot assay for prostate‐specific membrane antigen in serum of prostate cancer patients , 1994, The Prostate.

[52]  J. Mohler,et al.  Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues. , 1994, Biochemistry and molecular biology international.

[53]  T. Ravikumar,et al.  Ubiquitin-ribosomal protein S27a gene overexpressed in human colorectal carcinoma is an early growth response gene. , 1993, Cancer research.

[54]  King Cr,et al.  High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. , 1993 .

[55]  B. Grubeck‐Loebenstein,et al.  Stimulation of human thyroid growth via the inhibitory guanine nucleotide binding (G) protein Gi: constitutive expression of the G-protein alpha subunit Gi alpha-1 in autonomous adenoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Mafune,et al.  Increased expression of human ribosomal phosphoprotein P0 messenger RNA in hepatocellular carcinoma and colon carcinoma. , 1992, Cancer research.

[57]  S. Batra,et al.  Transfection of the human Muc 1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes. , 1991, Journal of cell science.

[58]  S. Batra,et al.  Molecular cloning and sequence analysis of the human ribosomal protein S16. , 1991, The Journal of biological chemistry.

[59]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[60]  I. Talbot,et al.  Identification of a human ribosomal protein mRNA with increased expression in colorectal tumours. , 1989, Biochimica et biophysica acta.

[61]  R. Matusik,et al.  Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. , 1986, Cancer research.

[62]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[63]  D P Byar,et al.  Orchiectomy for advanced prostatic carcinoma. A reevaluation. , 1973, Urology.

[64]  G. Wennemuth,et al.  Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread , 1999, Urological Research.

[65]  M. Tsai,et al.  Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. , 1999, Endocrinology.

[66]  T. Visakorpi,et al.  Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.

[67]  S. Chow,et al.  Identification of LDH-ras p21 protein complex and expression of these genes in human ovarian cancer. , 1997, Gynecologic Oncology.

[68]  S. Chow,et al.  Identification of LDH–rasp21 Protein Complex and Expression of These Genes in Human Ovarian Cancer☆ , 1997 .

[69]  R. Fotedar,et al.  Cell cycle control of DNA replication. , 1995, Progress in cell cycle research.

[70]  C. South.  Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis? , 1993 .

[71]  C. King,et al.  High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. , 1993, Cancer research.

[72]  M. Tainsky,et al.  Elevated expression of the ribosomal protein S2 gene in human tumors , 1992, Molecular carcinogenesis.

[73]  J. Holbrook,et al.  Cancer-associated lactate dehydrogenase is a tyrosylphosphorylated form of human LDH-A, skeletal muscle isoenzyme. , 1988, Cancer investigation.

[74]  J D Siegal,et al.  Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.